What smart money is saying about ProQR Therapeutics NV
PRQR
No fund has written a full thesis on ProQR Therapeutics NV in our archive, but 1 fund letter reports a position in it — most recently Platinium AM in June 2025.
Get an email when a fund buys, sells or pitches it
1
Reported positions
0
Bought
0
Sold
1
Letter
Position history
Every position in ProQR Therapeutics NV on record in the archive was reported in Q2 2025, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2025 | 1 | 0 | 0 | 0 |
Fund activity · 1 position
- HoldsPlatinium AMJune 2025
“Reading through M&A activity During the quarter Sanofi acquired Blueprint medicine for over $9b. The Fund has been increasing its position in Blueprint competitor Cogent Biosciences as we feel its drug bezuclastinib is competitive despite worries about its side effect profile. Cogent’s valuation has been very compelling (below $1b). Shortly after the quarter end, Cogent reported solid data for bezu which now puts it into a solid commercial position. Our RNA editing holding, ProQR (up 58% this quarter) also benefited from M&A readthrough.”
ProQR Therapeutics NV
Read the letters behind these ProQR Therapeutics NV positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger